Anticoagulant (AC) therapy, particularly aspirin, is associated with a reduced risk of prostate cancer-specific mortality (PCSM) among men treated with radical prostatectomy (RP) or radiotherapy (RT), a study found.
To examine the correlation between AC use and the risk of PCSM, Kevin S. Choe, MD, of the University of Texas Southwestern Medical Center in Dallas, and colleagues analyzed data from 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database diagnosed with localized adenocarcinoma of the prostate and treated with RP or RT.
The researchers found that 2,175 men (37%) were receiving ACs (warfarin, clopidogrel, enoxaparin, and/or aspirin), according to an online report in the Journal of Clinical Oncology. The risk of PCSM was significantly lower in the AC group compared with the non-AC group (3% vs. 8% at 10 years), as were the risks of disease recurrence and bone metastasis. The reduction in PCSM was most pronounced in patients with high-risk disease (4% vs. 19% at 10 years). Regardless of treatment modalities (RT or RP), benefit from AC was seen. In adjusted analyses, aspirin use was associated with a significant 57% decreased risk of PCSM.